Instem Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag

Instem (LON:INS) Full Year 2022 Results

Key Financial Results

• Revenue: UK£58.9m (up 28% from FY 2021).
• Net income: UK£4.70m (up 180% from FY 2021).
• Profit margin: 8.0% (up from 3.6% in FY 2021). The increase in margin was driven by higher revenue.
• EPS: UK£0.21 (up from UK£0.078 in FY 2021).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Instem EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) exceeded analyst estimates by 11%.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare Services industry in the United Kingdom.

Performance of the British Healthcare Services industry.

The company's shares are down 1.2% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Instem's balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.